Recent Updates
Recently added Catalysts
MDGL Positive Sentiment Score: 70/100

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Wednesday, February 8, 2023 1 min read
Key Takeaway: CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in three upcomi

Market Sentiment Analysis

POSITIVE FACTORS

  • Madrigal Pharmaceuticals is actively engaging with investors at multiple conferences.
  • The company's participation demonstrates confidence in its lead candidate and strategy.
  • The webcast availability of presentations allows for broader investor outreach.

Full Press Release Details

CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investor conferences:
SVB Securities Global Biopharma Conference
4:20 pm ET on Tuesday, February 14, 2023.
Cowen Annual Healthcare Conference
2:50 pm ET on Monday, March 6, 2023.
Oppenheimer Annual Healthcare Conference
10:40 am ET on Monday, March 13, 2023.
The presentations will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal website after the events.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit www.madrigalpharma.com.
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

Tags

Frequently Asked Questions

When will Madrigal Pharmaceuticals present at the SVB Conference?

Madrigal Pharmaceuticals will present at the SVB Securities Global Biopharma Conference at 4:20 pm ET on February 14, 2023.

What is Madrigal's lead candidate for treating NASH?

Madrigal's lead candidate for NASH is resmetirom, a thyroid hormone receptor-selective agonist.

Will the presentations be available for later viewing?

Yes, the presentations will be webcast and archived for replay on Madrigal's website.

What is nonalcoholic steatohepatitis (NASH)?

NASH is a liver disease characterized by fat buildup, with significant unmet medical needs.

How can I contact Madrigal Pharmaceuticals for investor inquiries?

Investor inquiries can be directed to Alex Howarth via email at IR@madrigalpharma.com.

Tags: MDGL Viatris Investor Conferences Healthcare Madrigal Pharmaceuticals investor conferences NASH therapeutics
Last updated: Feb 8, 2023